CMS quit test of pricey cancer treatment amid concerns over industry role image

Politico, July 9, 2018
By Sarah Karlin-Smith and David Pittman, quoting Rachel Sachs (Academic Fellow Alumna)


Read the full article

From the article:

“Coming from an administration which has a stated goal of trying to reduce drug pricing, trying to reduce overall drug spending and health care spending … at every turn this administration has taken steps in the opposite direction and this is one,” said Rachel Sachs, a professor who focuses on health law at Washington University in St. Louis.

Sachs said pay-for-performance deals can give drugmakers political cover to charge whatever they want if the companies can influence performance targets — in this case, with that short one-month timeline.

CMS said it has no formal agreement with any manufacturer for an outcomes-based price in a February letter to Rep. Lloyd Doggett, which came after months of inquiries from congressional Democrats over whether Novartis was getting favorable treatment on regulatory matters after paying Cohen.

Read more here!

fda health care finance health care reform health law policy pharmaceuticals rachel sachs